Clinical Trials Logo

Filter by:
NCT ID: NCT05755958 Active, not recruiting - Endometriosis Clinical Trials

Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms.

ENDO-HIFU-R2
Start date: February 3, 2023
Phase: N/A
Study type: Interventional

Rectal endometriosis (RE) induces lesions associated with painful symptoms that can alter quality of life. High Intensity Focused Ultrasound (HIFU) is a non-invasive ablative procedure using a high-intensity ultrasound probe to induce tissue devitalization using acoustic cavitation and thermal ablation. Focal One® is a transrectal HIFU device, which is validated to treat prostatic cancer. In this comparative, randomized, double blind study , the primary objective is to evaluate the efficacy of the HIFU treatment of rectal endometriosis with Focal One® HIFU device on the Acute Pelvic Pain 3 months after HIFU treatment, in comparison to a Sham group.

NCT ID: NCT05755789 Recruiting - Colorectal Surgery Clinical Trials

Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery

PROPHYLOXITIN
Start date: June 22, 2023
Phase: Phase 3
Study type: Interventional

The goal of this prospective, multicentre, double-blind, randomized clinical trial is to compare intermittent cefoxitin administration to loading bolus followed by continuous infusion for surgical antibiotic prophylaxis in colorectal surgery. The main objective is to demonstrate the superiority of a loading dose of cefoxitin followed by continuous infusion over standard of care boluses in reducing SSI within 30 days after colorectal surgery

NCT ID: NCT05755711 Recruiting - Clinical trials for Coronary Artery Disease

Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

EMPOWER CAD
Start date: May 3, 2023
Phase:
Study type: Observational

Post-market, prospective, multi-center, single-arm observational study to generate real-world clinical evidence associated with coronary IVL in a population of female subjects with calcified coronary artery disease.

NCT ID: NCT05755438 Recruiting - Prurigo Clinical Trials

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

TRuE-PN1
Start date: March 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

NCT ID: NCT05755386 Recruiting - IC-MPGN Clinical Trials

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

APPARENT
Start date: October 2, 2023
Phase: Phase 3
Study type: Interventional

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

NCT ID: NCT05755295 Recruiting - Neuroblastoma Clinical Trials

Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma

EQUI-HIPPO
Start date: April 3, 2023
Phase: N/A
Study type: Interventional

On average, each year in the former region, 60 new patients under the age of 18 are treated for a brain tumor, with an active post-treatment follow-up file of 350 patients. Because of the significant sequelae induced by the disease or the treatments, these patients will very often require rehabilitative care. The interest of involving the horse in the population of patients cured of a medulloblastoma but with important physical and psychological after-effects is to be able to combine a therapy using animal mediation (equitherapy) and a rehabilitation therapy based on the three-dimensional movement of the horse (hippotherapy).

NCT ID: NCT05755256 Recruiting - Acne Vulgaris Clinical Trials

The Impact of Probiotics on Skin Hydration in Youth With Mild Acne

YSH
Start date: September 4, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trials is to test the impact of probiotics on skin hydration in adolescents and young adults with mild acne. The hypothesis of this study is that the probiotic formulation is superior to placebo in improving the skin hydration in adolescents and young adults with minimal acne after 12 weeks of consumption.

NCT ID: NCT05754957 Recruiting - Clinical trials for Acute Coronary Syndrome

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

LIBREXIA-ACS
Start date: April 7, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).

NCT ID: NCT05754918 Recruiting - Clinical trials for Sensorineural Hearing Loss, Bilateral

Comparison in New Cochlear Implanted Subjects of a Tonotopy-based Fitting With or Without Fine Structure Coding

Start date: April 15, 2023
Phase: N/A
Study type: Interventional

Brief Summary: Main objective: Comparison of a tonotopy based fitting strategy (TFS) with fine structure coding to a tonotopy based fitting strategy without fine structure coding (TnoFS) for speech perception in noise. Secondary objectives: Comparison of TFS to TnoFS for the perception of musical elements (contour test). Comparison of TFS to TnoFS for speech perception in quiet Comparison of TFS to TnoFS for the qualitative preference for the listening of musical pieces. Comparison of TFS to TnoFS for the melodic recognition

NCT ID: NCT05754892 Recruiting - Cancer Clinical Trials

Positioning of Molecular Markers in Clinical Routine for the Management of Patients With Adrenal Cancers/Tumors (COMETE-CARE)

COMETE-CARE
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The adrenal cancer research network "COMETE" is federating French research on rare adrenal cancers. COMETE achieved major breakthroughs in the molecular characterization of adrenocortical carcinomas (ACC) and malignant pheochromocytomas/paragangliomas (MPP). Recently, COMETE successfully derived potential biomarkers for prognosis, theranostic and follow-up. Those biomarkers have been retrospectively validated. However the benefit for patients in real life conditions is not yet established. - Main objective : to implement COMETE biomarkers as a routine standard of care for adrenal cancer. - The primary end point is double : - Proportion of biomarkers results provided within 3 months after surgery, - The proportion of "informative" biomarkers, corresponding to markers passing quality controls and returning a value that is not in the grey zone of the measure. - Secondary objective : to estimate the impact of COMETE biomarkers on patients management. - Secondary endpoints : - Proportion of patients with discrepant clinical and molecular markers ; for discrepancies, proportion of decisions impacted by biomarkers results - Proportion of high risk patients for whom an actionable molecular target was identified - Predictive value (positive and negative) of biomarkers to detect recurrences - Molecular signatures of "extraordinary responders" to treatments (corresponding to the exceptional RECIST complete response, or to the >80% tumor reduction sutained for >6months)